×
About 2,313 results

ALLMedicine™ Acid Phosphatase Center

Research & Reviews  898 results

Targeting the spectrum of immune checkpoints in prostate cancer.
https://doi.org/10.1080/17512433.2021.1949287
Expert Review of Clinical Pharmacology; Sena LA, Denmeade SR et. al.

Jul 16th, 2021 - Introduction: The proven efficacy of the cellular vaccine sipuleucel-T in 2010 led to optimism about immunotherapeutic approaches for the treatment of prostate cancer. Some surmised that prostate cancer might be an ideal target for immune-mediated...

Spondylenchondrodysplasia mimicking a systemic lupus erythematosus: A diagnostic challe...
https://doi.org/10.1016/j.ejmg.2021.104286
European Journal of Medical Genetics; Bağlan E, Özdel S et. al.

Jul 11th, 2021 - Spondyloenchondrodysplasia (SPENCD) is a rare autosomal recessive skeletal dysplasia caused by biallelic mutations in the ACP5 gene that encodes tartrate-resistant acid phosphatase (TRAP). The extra-osseous phenotype of SPENCD is extremely pleiotr...

RANKL expression in chondrocytes and its promotion by lymphotoxin-α in the course of ca...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263262
PloS One; Takeshita A, Nishida K et. al.

Jul 9th, 2021 - We investigated the expression and localization of the receptor activator nuclear factor κB ligand (RANKL) in cartilage from patients with rheumatoid arthritis (RA) of relevance to cartilage degeneration. We also examined the role of exogenous lym...

Isolation and characterization of flavonoid compounds from Stachytarpheta jamaicensis (...
https://doi.org/10.1080/1354750X.2021.1950210
Biomarkers : Biochemical Indicators of Exposure, Response... Eskander DM, Aziz WM et. al.

Jul 8th, 2021 - Stomach ulcer is one of the most common gastrointestinal problems in the world. This study aimed to isolate flavonoid compounds from methanol extract of the aerial parts of Stachytarpheta jamaicensis (L.) Vahl. and evaluate its protective and ther...

TGM4: an immunogenic prostate-restricted antigen.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246381
Journal for Immunotherapy of Cancer; Lopez-Bujanda ZA, Obradovic A et. al.

Jul 2nd, 2021 - Prostate cancer is the second leading cause of cancer-related death in men in the USA; death occurs when patients progress to metastatic castration-resistant prostate cancer (CRPC). Although immunotherapy with the Food and Drug Administration-appr...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  7 results

Prostatic Acid Phosphatase (PAP) Vaccine in Patients With Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT00582140

Nov 19th, 2019 - The purpose of this research is to determine the safety of serial intradermal vaccinations of a DNA vaccine encoding human PAP, with GM-CSF as a vaccine adjuvant, in subjects with stage D0 prostate cancer. In addition, to determine whether PAP-spe...

Assessment of Tartrate-Resistant Acid Phosphatase (TRAP) as a Bone Resorption Marker in Stage IV Breast Cancer Patients With Bone Metastasis
https://clinicaltrials.gov/ct2/show/NCT00264082

Dec 29th, 2017 - The purpose of this research study is to evaluate the usefulness of the TRAP protein as (1) an early indicator of bone destruction and (2) a tool for assessing the effect of Zometa® in treating symptoms of bone metastases due to breast cancer. Tar...

Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients
https://clinicaltrials.gov/ct2/show/NCT01612299

Aug 7th, 2017 - Primary objectives: A. To evaluate the effect of Zortress® versus standard immunosuppression therapy on progression of CAC as evidenced by changes in Agatston scores from baseline and at 6, and 12 months in renal transplantation patients. B. To in...

Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone-Refractory Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT01897207

Aug 17th, 2015 - Dendritic cell (DC)-based immunotherapy is a promising approach to augment tumor antigen-specific T cell responses in cancer patients. However, tumor escape with down-regulation or complete loss of target antigens may limit the susceptibility of t...

APC8015 and Bevacizumab in Treating Patients With Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT00027599

Feb 11th, 2013 - OBJECTIVES: I. Determine the efficacy of APC8015 (Provenge) and bevacizumab, in terms of decline in prostate-specific antigen (PSA) value and effect on PSA doubling time, in patients with progressive prostate cancer. II. Determine any immune respo...

see more →

News  17 results

Sequential IV Ibandronate Tied to BMD Increase
https://www.medscape.com/viewarticle/942220

Dec 9th, 2020 - NEW YORK (Reuters Health) - Monthly intravenous ibandronate is associated with increases in bone mineral density (BMD) and bone microstructure benefits in women with osteoporosis after teriparatide treatment, according to new findings. Once teripa...

Romosozumab Has Biggest Effect in Treatment-Naive Patients
https://www.staging.medscape.com/viewarticle/936073

Aug 21st, 2020 - NEW YORK (Reuters Health) - Postmenopausal women with osteoporosis who are treatment-naive have the greatest early response to romosozumab (ROMO), according to new research. Improvements in lumbar spine (LS) and femoral neck (FN) bone-mineral dens...

Management of Castration-Resistant Prostate Cancer
https://www.mdedge.com/hematology-oncology/article/198157/genitourinary-cancer/management-castration-resistant-prostate/page/0/2?channel=214

Apr 3rd, 2019 - Treatment of Metastatic CRPC (M1 Disease) As with M0 CRPC, ADT should be continued in patients with mCRPC to maintain castration levels of testosterone while initiating additional treatments. Several drugs for the treatment of mCRPC have been appr.

Rethinking the Prostate Cancer Paradigm in the Urology Community
https://www.onclive.com/publications/urologists-in-cancer-care/2018/august-2018/rethinking-the-prostate-cancer-paradigm-in-the-urology-community

Aug 4th, 2018 - Raoul S. Concepcion, MD, FACS As we are all keenly aware, there is not a day that passes when our email inbox doesn’t include news of a genetic discovery that contributes to the ever-expanding body of knowledge in the prostate cancer world. The pr...

DNA vaccine + PD-1 blockade shows promise in mCRPC
https://www.mdedge.com/hematology-oncology/article/153953/immuno-oncology/dna-vaccine-pd-1-blockade-shows-promise-mcrpc
Sharon Worcester

Dec 9th, 2017 - NATIONAL HARBOR, MD. – Combining programmed death (PD)-1 blockade with tumor-targeted T-cell activation by a novel DNA vaccine safely enhanced antitumor immune responses in metastatic castration-resistant prostate cancer (mCRPC) patients in a rand.

see more →